A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25–50 mg) in patients with major depressive disorder / Sidney H. Kennedy en European Neuropsychopharmacology, Año 2014 - Vol. 24 - No.4 (Abril)

Público ISBD [artículo]  inEuropean Neuropsychopharmacology > Año 2014 - Vol. 24 - No.4 (Abril) . - pp. 553-563 Título : A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25–50 mg) in patients with major depressive disorder Tipo de documento: texto impreso Autores: Sidney H. Kennedy, Autor ; Alla S. Avedisova, Autor ; Natalia Giménez Montesinos, Autor Fecha de publicación: 2021 Artículo en la página: pp. 553-563 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Agomelatine, Depression, Placebo Resumen: A randomised placebo-controlled “dose relation study” was conducted in 549 patients who met the criteria for major depressive disorder, to evaluate the efficacy and safety of three doses regimens of agomelatine during 6 weeks: low fixed dosage (10 mg/day, n=133),... Link: ./index.php?lvl=notice_display&id=26975 [artículo] A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25–50 mg) in patients with major depressive disorder [texto impreso] / Sidney H. Kennedy, Autor ; Alla S. Avedisova, Autor ; Natalia Giménez Montesinos, Autor . - 2021 . - pp. 553-563. Idioma : Inglés (eng) Idioma original : Inglés (eng) in European Neuropsychopharmacology > Año 2014 - Vol. 24 - No.4 (Abril) . - pp. 553-563 Palabras clave: Agomelatine, Depression, Placebo Resumen: A randomised placebo-controlled “dose relation study” was conducted in 549 patients who met the criteria for major depressive disorder, to evaluate the efficacy and safety of three doses regimens of agomelatine during 6 weeks: low fixed dosage (10 mg/day, n=133),... Link: ./index.php?lvl=notice_display&id=26975

Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months / Sidney H. Kennedy en European Neuropsychopharmacology, Año 2016 - Vol. 26 - No.2 (Febrero)

Público ISBD [artículo]  inEuropean Neuropsychopharmacology > Año 2016 - Vol. 26 - No.2 (Febrero) . - pp. 378-389 Título : Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months Tipo de documento: texto impreso Autores: Sidney H. Kennedy, Autor ; Alla S. Avedisova, Autor ; Carole Belaïdi, Autor Fecha de publicación: 2021 Artículo en la página: pp. 378-389 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Agomelatina, Depresión, Placebo, Régimen de dosis, Largo plazo Resumen: This randomized placebo-controlled “dose relation study” was conducted in patients who met criteria for major depressive disorder, to evaluate the efficacy and safety of agomelatine during 24 weeks at 3 doses (i) low fixed dosage (10 mg/day, n=100 patients entered the extension period),... Link: ./index.php?lvl=notice_display&id=26620 [artículo] Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months [texto impreso] / Sidney H. Kennedy, Autor ; Alla S. Avedisova, Autor ; Carole Belaïdi, Autor . - 2021 . - pp. 378-389. Idioma : Inglés (eng) Idioma original : Inglés (eng) in European Neuropsychopharmacology > Año 2016 - Vol. 26 - No.2 (Febrero) . - pp. 378-389 Palabras clave: Agomelatina, Depresión, Placebo, Régimen de dosis, Largo plazo Resumen: This randomized placebo-controlled “dose relation study” was conducted in patients who met criteria for major depressive disorder, to evaluate the efficacy and safety of agomelatine during 24 weeks at 3 doses (i) low fixed dosage (10 mg/day, n=100 patients entered the extension period),... Link: ./index.php?lvl=notice_display&id=26620

---

1 (1 - 2 / 2)